Current Liabilities

Note payable to DIRECTV

Neurocrine Biosciences Note payable to DIRECTV decreased by 15.1% to $58.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 23.1%, from $47.70M to $58.70M. Over 5 years (FY 2020 to FY 2025), Note payable to DIRECTV shows an upward trend with a 31.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryLiquidity
SignalLower is better
VolatilityStable
First reportedQ4 2016
Last reportedQ1 2026May 5, 2026

How to read this metric

An increase suggests higher short-term debt reliance, while a decrease indicates the company is successfully paying down specific contractual obligations.

Detailed definition

This represents a short-term financial obligation owed to a specific corporate entity, categorized as a current liabilit...

Peer comparison

Similar to other 'Notes Payable' or 'Accounts Payable to Related Parties' found in the current liabilities section of peer balance sheets.

Metric ID: note_payable_directv

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$22.00M$20.00M$20.00M$17.60M$20.00M$18.10M$20.70M$18.40M$21.20M$18.70M$35.90M$36.70M$40.00M$37.00M$46.10M$47.70M$56.80M$53.70M$69.10M$58.70M
QoQ Change-9.1%+0.0%-12.0%+13.6%-9.5%+14.4%-11.1%+15.2%-11.8%+92.0%+2.2%+9.0%-7.5%+24.6%+3.5%+19.1%-5.5%+28.7%-15.1%
YoY Change-9.1%-9.5%+3.5%+4.5%+6.0%+3.3%+73.4%+99.5%+88.7%+97.9%+28.4%+30.0%+42.0%+45.1%+49.9%+23.1%
Range$17.60M$69.10M
CAGR+23.0%
Avg YoY Growth+36.0%
Median YoY Growth+29.2%

Frequently Asked Questions

What is Neurocrine Biosciences's note payable to directv?
Neurocrine Biosciences (NBIX) reported note payable to directv of $58.70M in Q1 2026.
How has Neurocrine Biosciences's note payable to directv changed year-over-year?
Neurocrine Biosciences's note payable to directv increased by 23.1% year-over-year, from $47.70M to $58.70M.
What is the long-term trend for Neurocrine Biosciences's note payable to directv?
Over 5 years (2020 to 2025), Neurocrine Biosciences's note payable to directv has grown at a 31.2% compound annual growth rate (CAGR), from $17.80M to $69.10M.
What does note payable to directv mean?
A short-term debt obligation owed to a specific business partner or related entity.